A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients.
The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature.



A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials.



Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations.



This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations.
Purdue University College of Pharmacy, West Lafayette, Indiana.
Tyler
T
Albright
Indiana University Health Arnett Nephrology, Lafayette, Indiana.
Akram
A
Al-Makki
Indiana University Health Arnett Nephrology, Lafayette, Indiana.
Rabih
R
Kalakeche
Departments of Experiential Learning and Pharmacy Practice, Purdue University College of Pharmacy, West Lafayette, Indiana. Electronic address: sheplerb@purdue.edu.
Brian
B
Shepler
D061605:Administration, Intravenous; D002951:Citrates; D019587:Dietary Supplements; D011756:Diphosphates / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood*; D006397:Hematinics / Q000008:administration & dosage; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy / Q000628:therapy
D002951:Citrates; D011756:Diphosphates; D006397:Hematinics; D006454:Hemoglobins; D005293:Ferritins; D007501:Iron; C049051:ferric pyrophosphate
anemia; chronic kidney disease; ferric pyrophosphate citrate; hemodialysis; hemoglobin; soluble ferric pyrophosphate